Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership.
“On behalf of the entire Board of Directors, we are pleased that Dr. Wills will serve as Chairman at this important time for Alpha Cognition,” said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. “He brings a wealth of experience, strategic insight, and a deep understanding of our business. The Board is confident that his leadership will help guide Alpha Cognition through its next phase of growth as we continue executing on the commercial launch of ZUNVEYL and advancing our pipeline to deliver meaningful therapies to patients.”
Dr. Wills has served on Alpha Cognition’s Board of Directors since 2025, and currently serves as Chair of the Governance and Nominating Committee and as a member of the Audit Committee. Dr. Wills currently serves as Chairman of the Board of Milestone Pharmaceuticals, Inc. (Nasdaq: MIST), and as a board member at Parion Sciences, Inc. He previously served as Chairman of the Board of CymaBay Therapeutics (Nasdaq: CBAY) prior to its acquisition by Gilead Sciences, Inc. in March 2024, as a board member at Oncternal Therapeutics (Nasdaq: ONCT) from 2019 to 2025, and as Executive Chairman of GTx, Inc. from 2015 to 2019. Prior to that, he spent more than 25 years at Johnson & Johnson, where his roles included Vice President, Alliance Management at the Janssen Pharmaceutical Companies and Senior Vice President, Global Development, in which he was responsible for the R&D pipeline and served as a member of the R&D Board of Directors. Dr. Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.
